Consensus Revvity, Inc.

Stocks

RVTY

US7140461093

Advanced Medical Equipment & Technology

Market Closed - NYSE 21:00:02 31/08/2026 BST			5-day change	1st Jan Change
128.67 ^USD	-0.10%		+4.61%	+32.99%

11:56am	RBC Initiates Revvity at Sector Perform With $135 Price Target	MT
08-11	Tranche Update on Revvity, Inc.'s Equity Buyback Plan announced on October 27, 2025.	CI

Evolution of the Average Target: Revvity, Inc.

Evolution of the Target Price: Revvity, Inc.

Changes in Analyst Recommendations: Revvity, Inc.

35503fd18cfc79c42a1f03eda.WPSAT2o9fo6E3E_zpDSc44i56RfBsF4gURTdBFKYs2Y.CKLtHTBHNMuwiCaA91rakuWI322l5zR6YHawSz3A-QcWrc0-J0ov9-GGGg~dfa21cb6a5b590f6c6415d5cae5e338e

Analysts' recommendations: Revvity, Inc.

11:56am	RBC Initiates Revvity at Sector Perform With $135 Price Target	MT
08-05	Bernstein Adjusts Price Target on Revvity to $120 From $115, Maintains Market Perform Rating	MT
08-05	Evercore ISI Adjusts Price Target on Revvity to $126 From $125, Maintains Outperform Rating	MT
08-05	Jefferies Adjusts Price Target on Revvity to $112 From $102, Maintains Hold Rating	MT
08-05	Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Equalweight Rating	MT
08-05	JPMorgan Adjusts Price Target on Revvity to $110 From $90	MT
08-05	Stifel Adjusts Price Target on Revvity to $110 From $100	MT
08-05	Analyst recommendations: Palantir Technologies, McDonald's, Booking Holdings, Arista Networks, Amgen...
07-15	TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating	MT
07-13	Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating	MT
07-06	Evercore ISI Adjusts Price Target on Revvity to $125 From $110	MT
05-04	Baird Adjusts Revvity Price Target to $125 From $129, Maintains Outperform Rating	MT
04-14	Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118	MT
04-13	Goldman Sachs Adjusts Price Target on Revvity to $95 From $110, Maintains Neutral Rating	MT
04-13	TD Cowen Adjusts Price Target on Revvity to $115 From $124, Maintains Buy Rating	MT
04-06	Evercore ISI Adjusts Revvity Price Target to $108 From $118, Maintains Outperform Rating	MT
03-31	JPMorgan Adjusts Price Target on Revvity to $96 From $105, Maintains Neutral Rating	MT
02-03	Wells Fargo Adjusts Price Target on Revvity to $110 From $107	MT
02-03	TD Cowen Adjusts Revvity PT to $124 From $120	MT
02-03	Baird Adjusts Price Target on Revvity to $129 From $123	MT
02-03	Raymond James Adjusts Price Target on Revvity to $132 From $115	MT
02-03	JPMorgan Adjusts Price Target on Revvity to $105 From $100	MT
02-03	Jefferies Adjusts Price Target on Revvity to $105 From $100	MT
02-03	Evercore ISI Adjusts Price Target on Revvity to $118 From $112	MT
02-03	Barclays Adjusts Price Target on Revvity to $118 From $115	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REVVITY, INC.					-5.91%
	THERMO FISHER SCIENTIFIC, INC.					+2.32%
	DANAHER CORPORATION					+6.74%
	INTUITIVE SURGICAL, INC.					+26.84%
	BOSTON SCIENTIFIC CORPORATION					+29.79%
	EDWARDS LIFESCIENCES CORPORATION					+11.25%
	SIEMENS HEALTHINEERS AG					+15.37%
	AGILENT TECHNOLOGIES, INC.					+13.57%
	WATERS CORPORATION					+5.99%
	RESMED, INC.					+2.56%
	Average					+10.85%
	Weighted average by Cap.					+11.50%